Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
98 stopped studies mapped to Castration-Resistant Prostate Carcinoma and descendants · 100% state a reason
Over the 98 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP… | Phase 1 | withdrawn | Apr 11, 2023 | National Cancer Institute (NCI) | No subjects enrolled in the study | Enrollment / accrual |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | Phase 1 / Phase 2 | terminated | Jul 7, 2020 | Institute of Cancer Research, United Kingdom | Funder decided that response outcomes to date did not support continuation of the study. | Other (stated, no rule matched) |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for… | Phase 2 | withdrawn | Jul 6, 2022 | National Cancer Institute (NCI) | Closed by study team, no subjects enrolled. | Enrollment / accrual |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One…(VERACITY) | Phase 3 | terminated | Apr 14, 2021 | Veru Inc. | Administrative reasons | Other (stated, no rule matched) |
| NCT05673109 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Jan 6, 2023 | Accutar Biotechnology Inc | Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study | Other (stated, no rule matched) |
| NCT05124795 | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Nov 18, 2021 | Immunic AG | Lack of Efficacy | Efficacy / futility |
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate…(REPAIR) | Phase 1 | suspended | Jun 21, 2022 | Peter MacCallum Cancer Centre, Australia | Enrolment suspended to further assess supplementary non-clinical study data. | Enrollment / accrual |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT05405439 | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in… | Phase 1 / Phase 2 | terminated | Jun 6, 2022 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The sponsor voluntarily terminated the study | Other (stated, no rule matched) |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double… | Phase 2 | terminated | Jun 26, 2019 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT03752099 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic… | Phase 1 / Phase 2 | terminated | Nov 23, 2018 | Veru Inc. | Administrative decision | Other (stated, no rule matched) |
| NCT05301062 | A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well…(CREDIT) | — | terminated | Mar 29, 2022 | Bayer | Due to the changes of standard of care, the slow recruitment of participants, and the similar… | Safety / toxicity |
| NCT05437679 | Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic…(CHARTER) | — | terminated | Jun 29, 2022 | Angle plc | Futility (slow enrollment) | Efficacy / futility |
| NCT04227275 | A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Jan 13, 2020 | Tceleron Therapeutics, Inc. | Based on the safety events and evidence of biologic activity without sustained clinical responses… | Safety / toxicity |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic… | Phase 1 / Phase 2 | terminated | Aug 5, 2022 | Tceleron Therapeutics, Inc. | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT04575766 | A Study of FT-7051 in Men With MCRPC | Phase 1 | terminated | Oct 5, 2020 | Novo Nordisk A/S | Sponsor Decision | Sponsor / business decision |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid… | Phase 1 | terminated | Sep 9, 2020 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | withdrawn | Mar 4, 2021 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT04077021 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Sep 4, 2019 | Calibr, a division of Scripps Research | Business decision | Sponsor / business decision |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | Phase 1 | withdrawn | May 10, 2021 | Syneos Health | Study abandoned, no participants enrolled | Enrollment / accrual |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon…(ESCALATE) | Phase 3 | terminated | Jan 23, 2020 | MANA RBM | The study was stopped due to insurmountable enrollment challenges affecting trial accrual,… | Enrollment / accrual |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant… | Phase 1 / Phase 2 | withdrawn | Oct 17, 2018 | Roswell Park Cancer Institute | lack of funding | Funding |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in… | Phase 1 | terminated | Feb 21, 2020 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With… | Phase 2 | terminated | May 22, 2018 | National Cancer Institute (NCI) | Study was closed for toxicity. | Safety / toxicity |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With… | Phase 1 | terminated | Nov 18, 2020 | Dizal Pharmaceuticals | Due to reasons of internal business strategy, not related to study or site conduct. | Sponsor / business decision |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous… | Phase 2 | terminated | Oct 19, 2018 | BeiGene | Sponsor's decision to revisit the development approach for prostate cancer. | Sponsor / business decision |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced… | Phase 1 / Phase 2 | terminated | Aug 9, 2019 | Pfizer | Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not… | Other (stated, no rule matched) |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic… | Phase 1 / Phase 2 | terminated | Oct 1, 2015 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy(RESIST-PC) | Phase 2 | terminated | Feb 3, 2017 | Endocyte | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT03261336 | Oral Calcitriol With Ketoconazole in CRPC | Phase 2 | terminated | Aug 25, 2017 | Donald Trump, MD | can not meet enrollment | Enrollment / accrual |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | Phase 1 / Phase 2 | terminated | Nov 15, 2018 | Jiangsu HengRui Medicine Co., Ltd. | According to the available data from the trial，the sponsor determined to terminate this study. | Other (stated, no rule matched) |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic… | Phase 1 / Phase 2 | terminated | May 2, 2018 | SOTIO a.s. | insufficient accrual | Enrollment / accrual |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT03596710 | Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With… | N/A | withdrawn | Jul 24, 2018 | Jonsson Comprehensive Cancer Center | sponsor withdrew study | Other (stated, no rule matched) |
| NCT03137758 | A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the… | Phase 1 | terminated | May 3, 2017 | Pellficure Pharmaceuticals, Inc | Reformulation of study drug to help reduce the pill burden as higher doses are evaluated. | Other (stated, no rule matched) |
| NCT01981109 | Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant…(PREDICT) | — | terminated | Nov 11, 2013 | Dendreon | Administrative reasons | Other (stated, no rule matched) |
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Oct 10, 2012 | University of Washington | Closed 2017 for low accrual. Last data for primary outcome on 02Feb2015. | Enrollment / accrual |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously…(COMET-2) | Phase 3 | terminated | Jan 31, 2012 | Exelixis | Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307. | Other (stated, no rule matched) |
| NCT02441517 | A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer… | Phase 4 | terminated | May 12, 2015 | Astellas Pharma Global Development, Inc. | The study is closed early due to lck of enrollment. | Enrollment / accrual |
| NCT01450683 | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy | Phase 2 | terminated | Oct 12, 2011 | Stanford University | Low accrual | Enrollment / accrual |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | Phase 2 / Phase 3 | terminated | Nov 11, 2013 | University Hospital, Grenoble | enrollment default | Enrollment / accrual |
| NCT02130947 | Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer… | N/A | withdrawn | May 6, 2014 | UNC Lineberger Comprehensive Cancer Center | We were not able to accrue any participants. | Enrollment / accrual |
| NCT02396368 | A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic…(Radium-223) | Phase 1 | withdrawn | Mar 24, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase III study results for the drug Tesquinimod were not promising so it was a drug development… | Other (stated, no rule matched) |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | terminated | Nov 25, 2009 | Sandy Srinivas | Decision by funding sponsor due to poor accrual | Enrollment / accrual |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In… | Phase 1 / Phase 2 | withdrawn | Feb 4, 2014 | Emmanuel Antonarakis, MD | This study was never able to open due to lack of funding from the pharmaceutical company. | Funding |
| NCT01663415 | A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve,… | Phase 2 | withdrawn | Aug 13, 2012 | Astellas Pharma Global Development, Inc. | A business decision was made to not initiate this study. | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 2, 2024source: clinicaltrials